- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05618496
Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients
February 6, 2024 updated by: Contipro Pharma a.s.
The main objective of the trial is to confirm safety of a new product - Epipad.
The main impact of the device is to provide good environment for the healing of chronic wounds and wounds in the last healing phase (granulation and epithelisation).
Study Overview
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brno, Czechia
- Fakultni nemocnice u sv. Anny
-
Hořice, Czechia
- Levitovo centrum nasledne pece
-
Olomouc, Czechia
- Vojenska nemocnice Olomouc
-
Vsetín, Czechia
- Vsetinska nemocnice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient suffered from superficial wound of different etiology
- Wounds in terminal phase of healing
- Wounds without visible sign of infection
- Max. size of the wound: 10 x 20 cm (i.e. two pieces of the product)
- Duration of wound treatment of at least 6 weeks
- Subject willing and able to provide written informed consent
- Ability to communicate well with the investigator in local language, and to understand and comply with the requirements of the study
Exclusion Criteria:
- Sloughy or necrotic wound bed
- Severely contaminated or infected wound
- Age < 18 years
- Pregnant or lactating woman
- Subject in terminal stage of living
- Subject with cancer disease
- Subject with known hypersensitivity or allergy to any component of the investigational device
- Subject participating in other interventional clinical trial
- Alcohol and/or drug abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients treated with Epipad
Epipad
|
Device is placed directly onto the treated wound.
The wound should be cleaned with antiseptic solution prior to the device administration.
The device is fixed on the wound by secondary dressing: e.g.
plaster, compression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the wound dimensions (width x length)
Time Frame: Week 3
|
Change in the wound dimensions from baseline
|
Week 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2022
Primary Completion (Actual)
October 31, 2023
Study Completion (Actual)
October 31, 2023
Study Registration Dates
First Submitted
November 9, 2022
First Submitted That Met QC Criteria
November 9, 2022
First Posted (Actual)
November 16, 2022
Study Record Updates
Last Update Posted (Actual)
February 8, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PT-EPI-1_09-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.